Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
Gene test proposed following neonatal encephalopathy
Wed August 5th - Gene profiling could predict outcomes for new born babies following oxygen deprivation, as well as help explain the mechanisms causing the damage, British researchers say. More
COVID-19 infection possible in early gestation
Wed August 5th - Genes which allow COVID-19 infection to take hold are present in the first trimester of pregnancy, researchers report today. More
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote: on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...

Gene hope for children's bone cancer treatment

Tuesday July 14th 2020

New genetic discoveries could lead to improved treatments for children with bone cancer – and save more lives.

A study by the University of East Anglia and University of Manchester has identified a set of genes that promote the spread of bone cancer to the lungs in patients. When the genes were tested in mice models with engineered human bone cancer cells, the cancer was unable to spread to the lungs of those lacking the key genes. The findings are published in Oncogene.

The researchers, led by Dr Darrell Green, of UEA’s Norwich Medical School, and Dr Katie Finegan from the University of Manchester, investigated osteosarcoma, the most common type of primary bone cancer whose genetic drivers are TP53 and RB1 structural variants.

Little is known about what drives its spread to other parts of the body, so the team developed new technology to isolate circulating tumour cells in patients’ blood.

Dr Green said primary bone cancer can rapidly spread to other parts of the body, making it the most problematic aspect because it is difficult to treat once it has spread.

Existing treatment options are gruelling, with outdated chemotherapy cocktails and limb amputation, but the five-year survival rate is 42% mainly because of how rapidly bone cancer spreads to the lungs.

After profiling tumours, circulating tumour cells (CTCs) and metastatic tumours from patient donors, the researchers identified MMP9 as a potential driver for metastasis, which is already well-known but it quickly becomes resistant to treatment.

The UEA researchers worked with a team at the University of Manchester, which was working on MAPK7, the proposed master regulator of MMP9, in several cancers using mouse models including osteosarcoma.

Together, they engineered human osteosarcoma cells containing a silenced version of MAPK7 and found when these cells were put into mice, the primary tumour grew much more slowly and did not spread to the lungs.

“If these findings are effective in clinical trials, it would no doubt save lives and improve quality of life because the treatment should be much kinder, compared to the gruelling chemotherapy and life changing limb amputation that patients receive today,” said Dr Green.

Senior author Dr Katherine Finegan, from the University of Manchester, added: “It has been great to work together with Darrell and the team at UEA. Using their genetic insights from patient material, we were able to validate their work in models of primary bone cancer. As a result, we have highlighted a potential new way to treat metastatic bone cancer by targeting a key protein that promotes metastases: MAPK7.

"This work has uncovered a novel treatment option for osteosarcoma, something we have not had for the last 40 years.”

Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene 13 July 2020

Tags: Cancer | Child Health | Genetics | UK News

Printer friendly page Printer friendly page

Comment on this article:

<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)